Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.69% for the 12-month period ending 2024-03-31, per its 10-K filed 2025-06-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-06-30
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.32%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-06-30 was 2.80%, a 16.67% increase year-over-year.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-06-30 was 2.40%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.69%, a 16.96% increase from fiscal 2023.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.01%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 2.40%, a 4.00% decline from fiscal 2017.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.50%, a 13.64% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2024-03-31 | 4.69% 10-K · filed 2025-06-30 | |||
| 2023-12-31 | 4.69% 10-Q · filed 2024-02-14 | |||
| 2023-09-30 | 4.32% 10-Q · filed 2023-11-14 | 4.32% 10-Q · filed 2023-11-14 | ||
| 2023-03-31 | 4.01% 10-K · filed 2024-07-01 | |||
| 2018-06-30 | 2.80% 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 2.40% 10-K · filed 2019-06-21 | |||
| 2017-12-31 | 2.40% 10-Q · filed 2018-02-09 | |||
| 2017-09-30 | 2.40% 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 2.40% 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 2.50% 10-K · filed 2018-06-14 | |||
| 2016-12-31 | 2.40% 10-Q · filed 2017-02-09 | |||
| 2016-09-30 | 2.20% 10-Q · filed 2016-11-09 | |||
| 2016-03-31 | 2.20% 10-K · filed 2018-06-14 | |||
| 2015-03-31 | 2.80% 10-K · filed 2017-06-14 |